Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alnylam And Takeda

RNAi specialist, Japanese drugmaker team up for Asian market in a deal worth up to $1 billion

by Rick Mullin
June 2, 2008 | A version of this story appeared in Volume 86, Issue 22

U .S.-based Alnylam Pharmaceuticals and Japan's Takeda Pharmaceutical have formed an alliance to develop RNA interference (RNAi) therapies. Under the terms of the five-year agreement, which has a potential value of $1 billion, Takeda will become the only company in Asia licensed to develop and commercialize therapies using Alnylam's RNAi therapeutic development program.

RNAi is a drug discovery research technique that employs the body's natural mechanisms for inhibiting the expression of genes. According to Alnylam, RNAi therapeutics target the cause of disease by silencing specific messenger RNAs, thereby preventing disease-causing proteins from being made.

Takeda will pay $100 million up front and $50 million in near-term technology transfer payments for a nonexclusive license to Alnylam's RNAi technology platform in the areas of oncology and metabolic disease.

Alnylam is also eligible to receive R&D funding and up to $171 million in development and commercial milestone payments plus unspecified royalties per product. Alnylam will attain a 50-50 development and commercialization stake in Takeda's RNAi therapeutic programs in the U.S.

"As the first RNAi technology partnership with a pharmaceutical company located in Asia, this new alliance expands the advancement of RNAi therapeutics to patients on a global basis," says John Maraganore, CEO of Alnylam.

Alnylam has already benefited from the scramble by major drug companies to access RNAi technology. Last year, Switzerland's Roche agreed to pay upwards of $1 billion for access to Alnylam's platform, acquiring its Kulmbach, Germany, research facilities.

Meanwhile, Merck & Co. paid $1.1 billion to acquire the RNA interference firm Sirna Therapeutics, and AstraZeneca took a $10 million stake in Silence Therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.